<?xml version="1.0" encoding="UTF-8"?>
<ref id="B128-jcm-09-01917">
 <label>128.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Dymek</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Sklepkiewicz</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Mlacki</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Zagozdzon</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Koralewski</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Mazur</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Paplinska-Goryca</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Nejman-Gryz</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Proboszcz</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Gorska</surname>
    <given-names>K.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): Anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis</article-title>
  <source>Eur. Respir. J.</source>
  <year>2018</year>
  <volume>52</volume>
  <fpage>OA5361</fpage>
  <pub-id pub-id-type="doi">10.1183/13993003.congress-2018.OA5361</pub-id>
 </element-citation>
</ref>
